ObsEva

99 articles about ObsEva

• ObsEva Announces Appointment of Annette Clancy as Chair of the Board of Directors

  5/19/2022

  ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced the appointment of Annette Clancy as Chair of the Board of Directors at the Company’s Annual General Meeting on May 18, 2022.

• ObsEva Announces First Quarter 2022 Financial Results and Provides Corporate Update

  5/17/2022

  ObsEva SA reported financial results for the first quarter ended March 31, 2022 and provided a business update.

• ObsEva to Present at the H.C. Wainwright Global Investment 2022 Conference

  5/16/2022

  ObsEva SA announced that Company Management will provide a corporate update at the upcoming H.C. Wainwright Global Investment Conference, taking place virtually and in Miami, Florida from May 23 – 26, 2022.

• ObsEva Announces Appointment of Dr. Brandi Howard as Chief Clinical Officer

  5/2/2022

  ObsEva SA announced the appointment of Dr. Brandi Howard as Chief Clinical Officer and member of the company’s Executive Committee, effective May 9, 2022.

• ObsEva Annual General Meeting 2022

  4/7/2022

  ObsEva SA published the invitation to its 2022 Annual General Meeting of Shareholders to be held on May 18, 2022 at 16:30 CEST at the company's offices in Geneva, Chemin des Aulx 12, 3rd floor, 1228 Plan-les-Ouates, Switzerland.

• ObsEva Annual Report 2021

  3/31/2022

  ObsEva SA, a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health, published its Annual Report 2021 to Shareholders.

• ObsEva Announces Year End 2021 Financial Results and Provides Corporate Update

  3/10/2022

  ObsEva SA, a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, reported financial results for the full year ended December 31, 2021 and provided a business update.

• ObsEva Appoints Katja Buhrer as Chief Strategy Officer

  2/1/2022

  ObsEva SA, a biopharmaceutical company developing and commercializing novel therapies for women’s health, announced the appointment of Katja Buhrer as Chief Strategy Officer and member of the company’s Executive Committee, effective February 1, 2022.

• ObsEva Announces Corporate Updates - Jan 28, 2022

  1/28/2022

  ObsEva SA announced that its board of directors approved on January 28, 2022 an increase of its share capital from 85,220,471 to 108,620,471 shares through the issuance of 23,400,000 newly registered shares at an issue price of 1/13 of a Swiss Franc each.

• 

  Clinical Catch-Up: January 3-7

  1/10/2022

  The biopharma industry has started 2022 with plenty of clinical trial news. Here’s a look.

• ObsEva Added to the NASDAQ Biotechnology Index

  12/20/2021

  ObsEva SA today announced it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective as of market open on Monday, December 20, 2021.

• ObsEva Announces Positive CHMP Opinion for Linzagolix, an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids

  12/17/2021

  ObsEva SA today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending approval of linzagolix.

• ObsEva Hosts Symposium and Presents Clinical Data on Oral GnRH Antagonist Linzagolix at SEUD Congress 2021

  12/10/2021

  ObsEva SA, a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, announced upcoming presentations of its linzagolix clinical development program at the 7th Society of Endometriosis and Uterine Disorders Congress being held virtually and in Stockholm, Sweden as a hybrid event from December 9-11, 2021.

• ObsEva Announces Symposium and Presentation of Clinical Data on Oral GnRH Antagonist Linzagolix at SEUD Congress 2021

  12/2/2021

  ObsEva SA announced a symposium and three oral presentations on linzagolix, an oral GnRH antagonist, at the 7th Society of Endometriosis and Uterine Disorders Congress being held virtually and in Stockholm, Sweden as a hybrid event from December 9-11, 2021.

• Obseva Announces U.S. FDA Acceptance of New Drug Application for Linzagolix

  11/22/2021

  Obseva SA announced that the New Drug Application for linzagolix for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women has been accepted for review by the United States Food and Drug Administration.

• Obseva Announces Appointment of Stephanie Brown to its Board of Directors

  11/22/2021

  ObsEva SA, a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, announced that Stephanie Brown has been selected to join its Board of Directors and will be proposed for election at the 2022 Annual General Meeting.

• ObsEva Announces Management Change

  10/29/2021

  ObsEva SA, a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, announced that current Chief Financial Officer David Renas will be stepping down from his position for personal reasons, effective January 5, 2022.

• ObsEva Announces Presentation of Clinical Data on Oral GnRH Antagonist Linzagolix at ASRM 2021 Scientific Congress & Expo

  10/19/2021

  ObsEva SA announced two upcoming poster presentations on linzagolix, an oral GnRH antagonist, at the American Society for Reproductive Medicine 2021 Scientific Congress & Expo, being held October 17-20, 2021.

• ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix

  10/13/2021

  ObsEva SA, a biopharmaceutical company dedicated to improving women’s reproductive health announced a strategic relationship with Syneos Health®, the only fully integrated biopharmaceutical solutions organization, to commercialize linzagolix.

• ObsEva Announces Submission of New Drug Application to U.S. FDA for Linzagolix for the Treatment of Uterine Fibroids

  9/15/2021

  ObsEva SA, a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration for linzagolix for the treatment of uterine fibroids.